Tobramycin
15 NDCs across 15 manufacturers|14 Generic,1 Brand
Tobramycin is used to treat infectious bone diseases, central nervous system infections, bacterial eye infections, intraabdominal infections, pseudomonas infections and respiratory tract infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Dec 13, 1984. In 2024, Medicare Part D spent $15 million on Tobramycin across 249,000 claims for 200,000 beneficiaries.
Tobramycin is available as 15 NDCs from 15 manufacturers (14 generic, 1 brand), with NADAC prices from $0.83 to $1.11 per ML — a 33% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
15
14G / 1B
Manufacturers
15
competing in market
Price Spread
$0.83 – $1.11
per ML, 14 of 15 NDCs
7d Activity
avg +1.6% WoW · of 15 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Novartis Pharmaceuticals Corporation manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Aminoglycoside Antibacterial class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
15 manufacturers producing TOBRAMYCIN(4 pricing outliers)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
TOBREX 0.3% EYE OINTMENT | $84.4145 per GM | -0.12% |
TOBRAMYCIN 0.3% EYE DROP | $1.1081 per ML | -4.30% |
TOBRAMYCIN 0.3% EYE DROP | $1.1081 per ML | -4.30% |
TOBRAMYCIN 0.3% EYE DROP | $1.1081 per ML | -4.30% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 300 MG/5 ML AMPULE | $1.0840 per ML | -0.05% |
TOBRAMYCIN 80 MG/2 ML VIAL | $0.8315 per ML | +12.45% |
TOBRAMYCIN 80 MG/2 ML VIAL | $0.8315 per ML | +12.45% |
TOBRAMYCIN 80 MG/2 ML VIAL | $0.8315 per ML | +12.45% |
Frequently Asked Questions
What is Tobramycin used to treat?
Tobramycin is used to treat infectious bone diseases, central nervous system infections, bacterial eye infections, intraabdominal infections, pseudomonas infections and respiratory tract infections, per the National Library of Medicine's MED-RT classification.
When did Tobramycin become available as a generic?
FDA approved the first generic Tobramycin (ANDA) on Dec 13, 1984.
How much does Medicare spend on Tobramycin?
In 2024, Medicare Part D spent $15 million on Tobramycin across 249,000 claims for 200,000 beneficiaries.
How many Tobramycin products are on the market?
The Tobramycin drug market contains 15 NDCs from 15 manufacturers — 14 generic and 1 brand product.
What is the price range for Tobramycin?
NADAC reference prices for Tobramycin range from $0.8315 to $1.1081 per ML — a 33% difference between cheapest and most expensive. 1 additional product is priced per a different unit (e.g. liquids per ML) and isn't directly comparable.
Which manufacturers make Tobramycin?
15 manufacturers list Tobramycin in NADAC. Ranked by number of NDCs, the largest are Novartis Pharmaceuticals Corporation (1), Somerset Therapeutics, LLC (1), Sandoz Inc. (1), Bausch & Lomb Incorporated (1), Ritedose Pharmaceuticals, LLC (1).
How has the price of Tobramycin changed recently?
Over the past 7 days, 3 Tobramycin NDCs rose and 12 fell, with a market-wide average change of +1.6%.